Base de dados : LILACS
Pesquisa : C04.557.337.539.275 [Categoria DeCS]
Referências encontradas : 357 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 36 ir para página                         

  1 / 357 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-365260 LILACS-Express
Autor: Bahia, Daniella M. M; Chauffaille, Maria L. F; Romeo, Maura S; Dias-Silva, Magnus R; Kerbauy, José.
Título: Leucemia Mielóide Aguda t(8; 21) após tratamento de hipertiroidismo com iodo radioativo: Leucemia secundária? / Acute Myeloid Leukemia t(8; 21) after treatment for hyperthyroidism using radioactive iodine: Secondary Leukemia?
Fonte: Rev. bras. hematol. hemoter;24(2):137-138, abr.-jun. 2002. ilus.
Idioma: pt.
Resumo: Acute leukemia following treatment with Iodine131 is a rare event. The possible carcinogenic effect of Iodine131 is still not clear and a large series of cases did not show an increased incidence of cancer. A case of AML t(8;21), three years after Iodine131 treatment for hyperthyroidism, is reported. Secondary AML with t(8;21) is described following exposure to drugs that target topoisomerase II and radiotherapy. The controversial potential of Iodine131 as a leukemogenic agent and the fact that t(8;21) is also found in de-novo AML, emphasize the problem in establishing a relationship between these events although this potential can not be ruled out.
Descritores: Leucemia Mieloide Aguda
-Hipertireoidismo
Tipo de Publ: Carta
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  2 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1151212
Autor: Galván, M E; Fridman, C; Latini, B; Brusca, S; Penayo Zárate, M A; Buamscha, D.
Título: Urgencias hematooncológicas: desde la perspectiva del intensivista / Hematology/oncology urgencies: from the perspective of the intensivist
Fonte: Med. infant;27(2):192-199, Diciembre 2020.
Idioma: es.
Resumo: Entre los años 2000 y 2016 en Argentina, se reportaron al Registro Oncopediátrico Hospitalario Argentino (ROHA) 22.450 casos de cáncer en niños menores de 15 años de edad. Las Leucemias constituyen la enfermedad oncológica más frecuente, seguida de los Tumores de Sistema Nervioso Central y los Linfomas. Esta distribución es similar a la descripta en los países desarrollados de Europa y Norteamérica. Su tasa de curación a nivel mundial, llega al 80% debido al uso de quimioterapia intensiva, situación que mejora la supervivencia pero que también aumenta la frecuencia de complicaciones. Estas complicaciones pueden ser debidas tanto al propio cáncer como al tratamiento y en ocasiones ser la primera manifestación de la enfermedad oncológica. Los eventos que amenazan la vida en pacientes inmunocomprometidos son mayores que en la población general, y cuando ocurren tienen una mortalidad elevada. El reconocimiento temprano es clave para el resultado en términos de sobrevida y disminución de la mortalidad. Las acciones deberán centrarse al reconocimiento temprano de eventos críticos en pacientes oncológicos. Los pacientes Hemato-Oncológicos constituyen un gran número de ingresos no planificados a las unidades de cuidados intensivos. Uno de cada 4 pacientes requerirá durante su evolución ingreso a Unidades de Cuidados Intensivos. El propósito de este artículo es describir tres de las urgencias oncológicas que requieren con mayor frecuencia admisión en UCI: la presentación y manejo del shock séptico, Shock Cardiogénico y las complicaciones neurológicas en los pacientes con leucemias agudas (AU)

Between 2000 and 2016, 22,450 cases of cancer in children younger than 15 years of age were reported to the Argentine Hospital Registry of Childhood Cancer (ROHA). Leukemia was the most common cancer reported, followed by central nervous system tumors and lymphoma. This distribution is similar to that described in the developed countries of Europe and North America. The worldwide cure rate is up to 80% due to the use of intensive chemotherapy, which improves survival but also increases the complication rate. These complications may be due both to the cancer itself and to the treatment and are sometimes the first manifestation of the disease. Life-threatening events are more common in immunocompromised patients than in the general population, and when they occur, the mortality rate is high. Early recognition is essential for the outcome in terms of survival and decreased mortality. Interventions should focus on early recognition of critical events in cancer patients. Patients with hematology-oncology diseases account for a large number of unplanned admissions to intensive care units (ICU), while one in four of these patients will require admission to the ICU in the course of their disease. The aim of this study was to describe three oncology emergencies that most frequently require ICU admission: septic shock and its management, cardiogenic shock, and neurological complications in patients with acute leukemia (AU)
Descritores: Choque Cardiogênico/etiologia
Choque Cardiogênico/terapia
Choque Séptico/etiologia
Choque Séptico/terapia
Unidades de Terapia Intensiva Pediátrica
Leucemia Mieloide Aguda/complicações
Doenças do Sistema Nervoso Central/etiologia
Doenças do Sistema Nervoso Central/terapia
Neoplasias Hematológicas/complicações
Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações
-Taxa de Sobrevida
Estado Terminal/terapia
Limites: Humanos
Lactente
Pré-Escolar
Criança
Adolescente
Responsável: AR305.1 - SID - Servicio de Información y Documentación


  3 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Id: biblio-1156567
Autor: Rodriguez Fraga, Yusaima.
Título: Panmielosis aguda con mielofibrosis / Acute panmyelosis with myelofibrosis
Fonte: Rev. cuba. med;60(1):e1349graf.
Idioma: es.
Resumo: La panmielosis aguda con mielofibrosis (PMAF) es un raro desorden hematológico, definido como un subtipo de leucemia aguda. Se reporta un paciente masculino de 31 años de edad con historia de decaimiento marcado, fiebre vespertina y gingivorragia. El examen físico muestra palidez cutáneo mucosas, esplenomegalia ligera y en exámenes complementarios pancitopenia con 5 por ciento de blastos. En el medulograma no se obtuvo material y la impronta sugiere leucemia mieloide aguda no promielocítica. El estudio de inmunofenotipo por citometría de flujo confirma incremento de mieloblastos positivo para (CD34, CD13, CD17, CD117, CD38) y disminuidos en (CD11c y HLA-DR), con una mielofibrosis marcada en biopsia de medula ósea sin la presencia de blastos. Recibe tratamiento de inducción con esquema 3 + 7 (Citosar + Rubidomicina) después del cual el paciente se encuentra en remisión hematológica con persistencia de la fibrosis medular. Posteriormente inicia tratamiento con lenalidomida, Bifosfonatos (Ácido Zoledronico) y se encuentra en remisión hematológica 11 meses después del diagnóstico, hasta marzo 2020. Se realizan estudios de histocompatibilidad (HLA) para trasplante alogénico(AU)

Acute panmyelosis with myelofibrosis (PMAF) is a rare hematologic disorder, defined as a subtype of acute leukemia. A 31-year-old male patient with a history of marked decay, evening fever, and gingivorrhagia is reported. The physical examination showed mucous skin paleness, slight splenomegaly and the complementary examinations showed pancytopenia with 5 percent blasts. In the medullogram no material was obtained and the imprint suggests non-promyelocytic acute myeloid leukemia. Immunophenotype study by flow cytometry confirmed an increase in myeloblasts positive for (CD34, CD13, CD17, CD117, CD38) and decreased in (CD11c and HLA-DR), with marked myelofibrosis in bone marrow biopsy without the presence of blasts. He received induction treatment with a 3 + 7 scheme (Citosar + Rubidomycin) after which the patient was in hematological remission with persistence of spinal fibrosis. Later, he started treatment with lenalidomide, bisphosphonates (Zoledronic Acid) and was in hematological remission 11 months after diagnosis, until March 2020. Histocompatibility studies (HLA) were performed for allogeneic transplantation(AU)
Descritores: Leucemia Mieloide Aguda/tratamento farmacológico
Leucemia Mieloide Aguda/epidemiologia
Doenças Mieloproliferativas-Mielodisplásicas/diagnóstico
Mielofibrose Primária
Limites: Humanos
Responsável: CU1.1 - Biblioteca Médica Nacional


  4 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: lil-765518
Autor: Combariza-Vallejo, Juan Felipe.
Título: Cohorte de supervivencia en pacientes menores de 60 años con leucemia mieloide aguda de acuerdo con la citogenética y el tratamiento de consolidación / Survival cohort of patients under 60 years with acute myeloid leukemia according to cytogenetics and consolidation treatment / Coorte de sobrevivência em pacientes menores de 60 anos com leucemia mielóide aguda de acordo com a citogenética e o tratamento de consolidação
Fonte: Iatreia;28(4):378-387, oct.-dic. 2015. ilus, tab.
Idioma: es.
Resumo: Introducción: la supervivencia de pacientes con leucemia mieloide aguda (LMA) puede variar de acuerdo con el cariotipo y el tratamiento recibido. Métodos: en esta cohorte retrospectiva se evaluaron la supervivencia, sus factores pronósticos y su asociación con el cariotipo inicial, en 66 pacientes con LMA menores de 60 años, que recibieron quimioterapia o trasplante alogénico de médula ósea. Resultados: la supervivencia global a 2 años fue del 90 % para el grupo de bajo riesgo, del 61 % para el de riesgo intermedio y del 30 % para el de riesgo alto (p = 0,016). Se hallaron como factores que afectan la supervivencia global el no haber alcanzado la remisión completa (HR: 16,36; IC 95 %: 6,17-43,33) y el no recibir trasplante de progenitores hematopoyéticos (HR: 4,76; IC 95 %: 1,36-16,69). Como factores de riesgo para la recaída de la enfermedad se identificaron el cariotipo de alto riesgo (HR: 9,18; IC 95 %: 1,22- 68,56) y la no realización de trasplante (HR: 3,06; IC 95 %: 1,14-8,18). Conclusión: este estudio sugiere que en Colombia la supervivencia global de los pacientes con LMA con riesgo citogenético intermedio o alto puede mejorar cuando reciben como parte del tratamiento el trasplante de progenitores hematopoyéticos.

Introduction: Survival of patients with acute myeloid leukemia (AML) differs according to karyotype and the treatment they receive. Methods: In this retrospective cohort we evaluated survival, its prognostic factors and its association with the initial karyotype in 66 patients younger than 60 years with AML, who received chemotherapy or allogeneic bone marrow transplantation. Results: Overall survival at 2 years was 90 % in the low risk group, 61 % in the intermediate risk group and 30 % in the high risk group (p = 0.016). The following factors affected overall survival: not having reached complete remission (HR: 16.36; IC 95 %: 6.17-43.33), and not having received haematopoietic stem cell transplantation (HR: 4.76; IC 95 %: 1.36-16.69). As risk factor for relapse we found: High risk karyotype (HR: 9.18; IC 95 %: 1.22- 68.56) and not having performed haematopoietic stem cell transplantation (HR: 3.06; IC 95 %: 1.14-8.18). Conclusion: This study suggests that in Colombia the global survival of young patients with AML with intermediate or high cytogenetic risk at diagnosis may improve when they receive hematopoietic stem cell transplantation as part of the treatment.

Introdução: a sobrevivência de pacientes com leucemia mielóide aguda (LMA) pode variar de acordo com o cariótipo e o tratamento recebido Métodos: nesta coorte retrospectiva se avaliaram a sobrevivência, seus fatores prognósticos e sua associação com o cariótipo inicial, em 66 pacientes com LMA menores de 60 anos, que receberam quimioterapia ou transplante alogênico de medula óssea. Resultados: a sobrevivência global a 2 anos foi do 90 % para o grupo de baixo risco, do 61 % para o de risco intermédio e do 30 % para o de risco alto (p = 0,016). Acharam-se como fatores que afetam a sobrevivência global o não ter atingido a remessa completa (HR: 16,36; IC 95 %: 6,17-43,33) e o não receber transplante de progenitores hematopoiéticos (HR: 4,76; IC 95 %: 1,36-16,69). Como fatores de risco para a recaída da doença se identificaram o cariótipo de alto risco (HR: 9,18; IC 95 %: 1,22- 68,56) e a não realização de transplante (HR: 3,06; IC 95 %: 1,14-8,18). Conclusão: este estudo sugere que na Colômbia a sobrevivência global dos pacientes com LMA com risco citogenético intermédio ou alto pode melhorar quando recebem como parte do tratamento o transplante de progenitores hematopoiéticos.
Descritores: Leucemia Mieloide Aguda
Citogenética
Tratamento Farmacológico
-Estudos Retrospectivos
Limites: Humanos
Adulto
Tipo de Publ: Artigo Clássico
Responsável: CO332 - Facultad de Medicina


  5 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Saúde Pública
Texto completo
Id: biblio-890531
Autor: Barsaglini, Reni Aparecida; Soares, Beluci Bianca Nunes de Siqueira.
Título: Impactos de adoecimento de longa duração: experiência de adultos jovens com Leucemia Mieloide Aguda / Impacts of long-term illness: experience of young adults with Acute Myeloid Leukemia
Fonte: Ciênc. Saúde Colet;23(2):399-408, Fev. 2018. tab.
Idioma: pt.
Resumo: Resumo O presente artigo analisa os impactos materiais e imateriais imersos na experiência de adultos jovens com um adoecimento de longa duração - Leucemia Mieloide Aguda. Decorre de pesquisa mais ampla, inspirada na Fenomenologia de Alfred Schutz. Os dados foram obtidos por entrevistas em profundidade com quatro jovens, de 20 a 28 anos, em fase de manutenção no tratamento oncológico, entre novembro de 2013 a janeiro de 2014, em Mato Grosso. Os resultados enfocam aspectos marcantes dos impactos na experiência como o processo de descoberta da enfermidade em que o diagnóstico provocou sentimentos mobilizados por ideias sobre uma doença grave. Seguem-se os impactos na aparência devidos ao tratamento, sobressaindo a queda de cabelo e as estratégias cotidianas de enfrentamento, bem como o aumento ou a perda de peso. Por fim, é marcante o impacto da iminência da morte diante da letalidade da doença e o testemunho da ocorrência em pessoas conhecidas, colocando-a como possibilidade concreta para si, mas também como sobreviventes. Os impactos são os efeitos e as transformações na vida das pessoas e seu entorno e evocam (re) ações, contudo, diluem-se na experiência compondo-a, e não sendo homogênea, sua abordagem privilegia a singularidade inscrita em biografias contextualizadas.

Abstract This article analyzes the tangible and intangible impacts involved in the experience of young adults diagnosed with a long-term illness, namely Acute Myeloid Leukemia. It follows on from broader research, inspired by the Phenomenology of Alfred Schutz. The data were obtained through in-depth interviews with four young adults, aged between 20 and 28, who were in the maintenance phase of cancer treatment between November 2013 and January 2014 in the State of Mato Grosso. The results focus on striking aspects of the impacts of the experience during the process of becoming aware of the illness in which the diagnosis provoked feelings mobilized by ideas regarding a serious illness. This is followed by the impacts on appearance due to the treatment, especially hair loss and day-to-day coping strategies, as well as weight gain or loss. Finally, there is the marked impact of the imminence of death due to the lethality of the disease and the testimony of the occurrence in friends and family, but also for the survivors. The impacts are the effects and transformations in the lives of people and their relations and evoke (re)actions, however, they are diluted in the experience composing it, and not being homogeneous, its approach addresses the singularity encountered in contextualized biographies.
Descritores: Adaptação Psicológica
Leucemia Mieloide Aguda/terapia
Alopecia/etiologia
Sobreviventes de Câncer/psicologia
-Leucemia Mieloide Aguda/psicologia
Atitude Frente a Morte
Família/psicologia
Entrevistas como Assunto
Amigos/psicologia
Alopecia/psicologia
Limites: Humanos
Masculino
Feminino
Adulto
Adulto Jovem
Responsável: BR1.1 - BIREME


  6 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1115511
Autor: Laguna-Olmos, Mariano; Esteban-Figuerola, Ada; Ruiz-Peña, Ana Cristina; Díaz-Rabasa, Beatriz; Fernández García, Cristina; Arrieta-Bretón, Sara; Vilas-Saura, Lucía; Peralta-Benitez, Raiza Soraya.
Título: Leucemia mieloide aguda y pre-eclampsia coexistente: algunas dificultades diagnósticas: a propósito de un caso / Acute myeloid leukemia and coexisting preeclampsia: some diagnosis difficulties: a case report
Fonte: Rev. chil. obstet. ginecol. (En línea);85(2):155-161, abr. 2020. tab, graf.
Idioma: es.
Resumo: OBJETIVO: Remarcar la importancia de hacer un adecuado diagnóstico diferencial de la anemia y trombocitopenia en la gestante, ya que en ocasiones enmascaran cuadros tan graves como la leucemia. Presentar un caso de leucemia mieloide aguda con una preeclampsia sobreañadida y describir el proceso diagnóstico y terapéutico llevado a cabo. CASO CLÍNICO: Secundigesta, 25 años, gestante de 37 semanas, con antecedentes de preeclampsia, derivada desde atención primaria por alteración analítica y malestar general. A su llegada a urgencias el cuadro clínico es compatible con un Síndrome de HELLP. Tras el estudio del mismo se llega a la certeza de que se trata de una preeclampsia asociada a una leucemia mieloide aguda que ha simulado los parámetros analíticos de un Síndrome de HELLP. CONCLUSIONES: Es importante el adecuado estudio etiológico de la anemia y trombocitopenia en la gestación. La leucemia exige al clínico un abordaje precoz y multidisciplinar tanto diagnóstico como terapéutico.

OBJECTIVE: To emphasize on the importance of performing a precise differential diagnosis of anaemia and thrombocytopenia during pregnancy, as they can be due to important diseases as leukemia. A case of acute myeloid leukemia associated with preeclampsia is reported, describing the complexity of the diagnostic and therapeutic process. CLINICAL CASE: 25-year-old woman, gravida 2, para 1 (preeclampsia), at 36 weeks of gestation was referred to the emergency department by her primary care physician due to severe disturbance on the blood tests and general discomfort. Initially, a HELLP syndrome was suspected. However, after going in depth in the case, the final diagnosis was preeclampsia associated to acute myeloid leukemia, simulating blood parameters in HELLP syndrome. CONCLUSIONS: It is essential to study deeply and carry out a complete differential diagnosis process of anaemia and thrombocytopenia during pregnancy. Leukemia requires an early multidisciplinary management both for diagnosis and treatment.
Descritores: Pré-Eclâmpsia/diagnóstico
Complicações Neoplásicas na Gravidez
Leucemia Mieloide Aguda/complicações
Leucemia Mieloide Aguda/diagnóstico
-Trombocitopenia/etiologia
Síndrome HELLP/diagnóstico
Diagnóstico Diferencial
Anemia/etiologia
Limites: Humanos
Feminino
Adulto
Tipo de Publ: Relatos de Casos
Responsável: CL1.1 - Biblioteca Central


  7 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1011413
Autor: Zhang, Feng; Li, Jiajia; Zhu, Junfeng; Liu, Lin; Zhu, Kai; Cheng, Shuang; Lv, RuDi; Zhang, Pingping.
Título: IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells
Fonte: Biol. Res;52:11, 2019. graf.
Idioma: en.
Projeto: Anhui University Natural Science Research; . Key Project of Natural Science Foundation of Bengbu Medical College.
Resumo: BACKGROUND: The present study aimed to investigate the underlying role of interferon-regulatory factor 2 (IRF2)-inositol polyphosphate-4-phosphatase, type-II (INPP4B) axis in the regulation of autophagy in acute myeloid leukemia (AML) cells. METHODS: Quantitative real time PCR (QRT-PCR) and western blot were performed to determine the expression levels of IRF2, INPP4B and autophagy-related markers in AML cell lines. Autophagy was assessed by elevated Beclin-1 expression, the conversion of light chain 3 (LC3)-I to LC3-II, downregulated p62 expression and green fluorescent protein (GFP)-LC3 puncta formation. The colony formation and apoptosis assays were performed to determine the effects of IRF2 and INPP4B on the growth of AML cells. RESULTS: IRF2 and INPP4B were highly expressed in AML cell lines, and were positively correlated with autophagy-related proteins. Overexpression of IRF2 or INPP4B stimulated autophagy of AML cells, whereas inhibition of IRF2 or INPP4B resulted in the attenuation of autophagy. More importantly, IRF2 or INPP4B overexpression reversed autophagy inhibitor, 3-methyladenine (3-MA)-induced proliferation-inhibitory and pro-apoptotic effects, while IRF2 or INPP4B silencing overturned the proliferation-promoting and anti-apoptotic effects of autophagy activator rapamycin. CONCLUSION: IRF2-INPP4B signaling axis attenuated apoptosis through induction of autophagy in AML cells.
Descritores: Autofagia
Leucemia Mieloide Aguda/metabolismo
Apoptose
Monoéster Fosfórico Hidrolases/metabolismo
Fator Regulador 2 de Interferon/metabolismo
-RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Leucemia Mieloide Aguda/patologia
Transdução de Sinais
Western Blotting
Imunofluorescência
Linhagem Celular Tumoral
Proliferação de Células
Reação em Cadeia da Polimerase em Tempo Real
Limites: Humanos
Responsável: CL1.1 - Biblioteca Central


  8 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Texto completo
Id: biblio-1149902
Autor: Ruiz Moleón, Vera; Díaz Alonso, Carmen Alina; Amor Vigil, Ana María; Fernández Martínez, Lesbia; Garrote Santana, Heidys; González García, Sheila.
Título: Caso atípico de leucemia mieloide aguda con coexistencia de NPM1-A e inversión del cromosoma 16 / A rare case of acute myeloid leukemia with coexistence of NPM1-A mutation and chromosome 16 inversion
Fonte: Rev. cuba. hematol. inmunol. hemoter;36(2):e1189, abr.-jun. 2020.
Idioma: es.
Resumo: Introducción: La leucemia mieloide aguda (LMA) es un grupo heterogéneo de desórdenes clonales con una gran variabilidad en términos de patogénesis, características morfológicas, genéticas e inmunofenotípicas. Las mutaciones en el gen NPM1 representan una de las más comunes en las LMA y está asociada con una respuesta clínica favorable. Por citogenética, la inversión del cromosoma 16 define el subgrupo de las LMA de factor de unión al grupo con un pronóstico favorable. Objetivo: Describir un caso con diagnóstico de LMA en los cuales el estudio molecular del gen NPM1 y de la inv(16) fueron positivos. Caso clínico: A nivel molecular, la hibridación in situ fluorescente fue positivo a la inv(16) y por biología molecular fue positivo tanto a la inv(16) como al gen NPM1-A, elementos de baja frecuencia de aparición. Se le administró a la paciente un esquema de poliquimioterapia no intensiva para mejorarla clínicamente. Después de una mejoría clínica inicial, la paciente comenzó con complicaciones y falleció. Conclusiones: La coexistencia de estas dos mutaciones es muy poco frecuente en pacientes con LMA, y a pesar de ser de buen pronóstico la paciente falleció a los pocos días de tratamiento(AU)

Introduction: Acute myeloid leukemia (AML) is a heterogeneous group of clonal disorders with great variability in terms of pathogenesis, morphological, genetic and immunophenotypic characteristics. NPM1 mutations represent one of the most common in AML and are associated with favorable clinical response. By cytogenetics, chromosome 16 inversion defines, with a favorable prognosis, the core‐binding factor for the subgroup of AMLs Objective: To describe a AML case in which the molecular study of the NPM1 gene and the chromosome 16 inversion were positive. Clinical case: At the molecular level, fluorescent in situ hybridization was positive for chromosome 16 inversion and, by molecular biology, it was positive for both chromosome 16 inversion and for the NPM1-A gene, elements with a low frequency of appearance. The patient was administered a non-intensive combination as part of a chemotherapy regimen to improve her clinical status. After initial clinical improvement, the patient began with complications and died. Conclusions: The coexistence of these two mutations is very rare in patients with AML. Despite presenting a good prognosis, the patient died after a few days of treatment(AU)
Descritores: Cromossomos Humanos Par 16/genética
Leucemia Mieloide Aguda/diagnóstico
Mutação/genética
-Hibridização in Situ Fluorescente/métodos
Quinase do Linfoma Anaplásico/genética
Limites: Humanos
Feminino
Tipo de Publ: Relatos de Casos
Responsável: CU1.1 - Biblioteca Médica Nacional


  9 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1011428
Autor: Feng, Yubin; Hua, Xiaoxiao; Niu, Ruowen; Du, Yan; Shi, Congjian; Zhou, Renpeng; Chen, Fei-Hu.
Título: ROS play an important role in ATPR inducing differentiation and inhibiting proliferation of leukemia cells by regulating the PTEN/PI3K/AKT signaling pathway
Fonte: Biol. Res;52:26, 2019. graf.
Idioma: en.
Projeto: National Major Scientific and Technological Special Project.
Resumo: BACKGROUND: Acute myeloid leukemia (AML) is an aggressive and mostly incurable hematological malignancy with frequent relapses after an initial response to standard chemotherapy. Therefore, novel therapies are urgently required to improve AML clinical outcomes. 4-Amino-2-trifluoromethyl-phenyl retinate (ATPR), a novel all-trans retinoic acid (ATRA) derivative designed and synthesized by our team, has been proven to show biological anti-tumor characteristics in our previous studies. However, its potential effect on leukemia remains unknown. The present research aims to investigate the underlying mechanism of treating leukemia with ATPR in vitro. METHODS: In this study, the AML cell lines NB4 and THP-1 were treated with ATPR. Cell proliferation was analyzed by the CCK-8 assay. Flow cytometry was used to measure the cell cycle distribution and cell differentiation. The expression levels of cell cycle and differentiation-related proteins were detected by western blotting and immunofluorescence staining. The NBT reduction assay was used to detect cell differentiation. RESULTS: ATPR inhibited cell proliferation, induced cell differentiation and arrested the cell cycle at the G0/G1 phase. Moreover, ATPR treatment induced a time-dependent release of reactive oxygen species (ROS). Additionally, the PTEN/PI3K/Akt pathway was downregulated 24 h after ATPR treatment, which might account for the anti-AML effects of ATPR that result from the ROS-mediated regulation of the PTEN/PI3K/AKT signaling pathway. CONCLUSIONS: Our observations could help to develop new drugs targeting the ROS/PTEN/PI3K/Akt pathway for the treatment of AML.
Descritores: Retinoides/farmacologia
Espécies Reativas de Oxigênio/metabolismo
Antineoplásicos/farmacologia
-Fluorimunoensaio
Leucemia Mieloide Aguda
Transdução de Sinais
Regulação para Baixo
Diferenciação Celular/efeitos dos fármacos
Sobrevivência Celular/efeitos dos fármacos
Fosfatidilinositol 3-Quinases/metabolismo
Linhagem Celular Tumoral
Proliferação de Células/efeitos dos fármacos
PTEN Fosfo-Hidrolase/efeitos dos fármacos
PTEN Fosfo-Hidrolase/metabolismo
Proteínas Proto-Oncogênicas c-akt/efeitos dos fármacos
Proteínas Proto-Oncogênicas c-akt/metabolismo
Limites: Humanos
Responsável: CL1.1 - Biblioteca Central


  10 / 357 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Texto completo
Id: biblio-1093275
Autor: Amor Vigil, Ana María; Hernández Miranda, Londy Lorena.
Título: La biología molecular en el diagnóstico de la leucemia mieloide aguda / Molecular biology in the diagnostic of acute myeloid leukemia
Fonte: Rev. cuba. hematol. inmunol. hemoter;35(3):e987, jul.-set. 2019.
Idioma: es.
Resumo: Introducción: La biología molecular ha permitido identificar los genes de fusión que se forman a consecuencia de reordenamientos cromosómicos aberrantes e identificar alteraciones moleculares no observables mediante la citogenética. En algunos casos, la presencia de alteraciones cromosómicas o moleculares correlaciona con determinados subtipos de leucemia mieloide aguda (LMA) definidos por sus características citomorfológicas. Sin embargo, en otros no sucede así, por lo que el conocimiento de ciertas alteraciones moleculares ha hecho posible la definición de nuevos subtipos de LMA. Objetivo: Esta revisión pretende destacar cómo la biología molecular ha cobrado importancia en el diagnóstico y pronóstico de las LMA. Desarrollo: Primero refiere las alteraciones moleculares más frecuentes que se forman debido a aberraciones cromosómicas. A continuación, se describen las mutaciones génicas que con mayor frecuencia aparecen en la LMA. Un tercer apartado, destaca las alteraciones de mayor impacto para el pronóstico. Finalmente, se describe cómo la clasificación de las LMA ha cambiado debido al descubrimiento progresivo de alteraciones moleculares que correlacionan con comportamientos particulares en cuanto a evolución y respuesta al tratamiento(AU)

Introduction: Molecular biology has allowed the identification of fusion genes formed as a consequence of aberrant chromosome rearrangement and to find molecular alteration not observed by cytogenetic. In occasion, the presence of some chromosomal or molecular alterations correlate with specific subtypes of acute myeloid leukemia (AML) previous defined by its cytomorphological features. However, in others cases there is not total correspondence with and the knowledge of molecular anomalies has been possible to define new subtypes of AML. Objective: To highlight how the molecular biology has been gain relevance for the diagnostic and prognostic of the AML. Development: First, are mentioned the more frequent molecular alterations formed a cause of chromosomal aberrations. After, are described the more frequent gene mutations appeared in AML cases. A third topic, point out the alterations of mayor impact for the prognostic. Finally, is described how has change the classification of AML because the progressive discovery of new molecular alterations that match with particular evolution and treatment response(AU)
Descritores: Leucemia Mieloide Aguda/diagnóstico
Leucemia Mieloide Aguda/diagnóstico por imagem
Biologia Molecular/métodos
-Prognóstico
Limites: Humanos
Masculino
Feminino
Tipo de Publ: Revisão
Responsável: CU1.1 - Biblioteca Médica Nacional



página 1 de 36 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde